
Empowering Upfront, Broad and Timely Molecular Pathology in Advanced NSCLC



Adv., advanced; CNB, core needle biopsy; EMR, electronic medical record; IHC, immunohistochemistry; FNA, fine needle aspiration; MDT, multidisciplinary team; MTB, molecular tumor board; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; QNS, quantity not sufficient; SGT, single gene test; SOP, standard operating protocol

1. Hanna NH, et al. J Clin Oncol. 2021;39(9):1040–1091; 2. Sadik H, et al. JCO Precision Oncol. 2022; 6: e220024; 3. Aisner D, et al. Arch Pathol Lab Med. 2016 Nov;140(11):1206–1220; 4. Fintelmann FJ, et al. Respir Res. 2023;24(1):17; 5. Roy-Chowdhuri S, et al. Arch Pathol Lab Med. 2020: 144 (8): 933–958; 6. Penault-Lorca F, et al. Virchows Arch. 2022 Sep;481(3):335–350; 7. Compton CC, et al. Arch Pathol Lab Med. 2019;143(11):1346–1363; 8. Ascierto PA, et al. J Mol. Diagn. 2019; 21(5):756–767; 9. Travis WD, et al. Arch Pathol Lab Med. 2013; 137(5):668–684; 10. Navani N, et al. Lung Cancer. 2022 Oct;172:142–153; 11. Ossowski S, et al. JCO Oncol Pract. 2022;18(11):e1874-e1884; 12. Fox AH, et al. CA Cancer J Clin. 2023;73(4):358–375; 13. Gregg JP, et al. Transl Lung Cancer Res. 2019; 8(3):286–301; 14. Kerr KM et al. Ann Oncol. 2016; 27(Suppl 3):iii16-iii24; 15. Cohen D, et al. J Thorac Oncol. 2020 Jun;15(6):1000–1014.